BIIB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

189.390

Open

186.160

VWAP

187.98

Vol

121.97K

Mkt Cap

26.98B

Low

186.160

Amount

22.93M

EV/EBITDA(TTM)

8.23

Total Shares

146.76M

EV

29.45B

EV/OCF(TTM)

13.36

P/S(TTM)

2.73

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Show More

Events Timeline

(ET)

2026-03-30

07:40:00

Biogen's Spinraza High-Dose Regimen Approved by FDA

2026-03-29 (ET)

2026-03-29

10:40:00

Biogen Reports Positive Results for Skin Lupus Drug

2026-03-20 (ET)

2026-03-20

12:20:00

Eisai and Biogen Release Long-Term Treatment Data for Lecanemab

2026-03-11 (ET)

2026-03-11

08:10:00

Biogen Presents Salanersen Study Results at Muscular Dystrophy Conference

2026-03-04 (ET)

2026-03-04

17:20:00

Stoke Therapeutics and Biogen Publish Zorevunersen Study Data

2026-02-11 (ET)

2026-02-11

17:10:00

Biogen Appoints Maria Freire as Chair of the Board

News

moomoo

PinnedFDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY

NASDAQ.COM

03:04 AMNASDAQ.COM

PinnedBiogen Reports Positive Results for Litifilimab in Lupus Study

NASDAQ.COM

20:04 PMNASDAQ.COM

US Stock Market Declines Amid Rising Oil Prices

NASDAQ.COM

19:04 PMNASDAQ.COM

Mixed U.S. Stock Indices Amid Rising Oil Prices

NASDAQ.COM

17:05 PMNASDAQ.COM

US Stocks Rise as Oil Prices Hit Three-Week High

seekingalpha

16:11 PMseekingalpha

FDA Approves Biogen's New High-Dose Spinraza Regimen

26 Analyst Rating

Wall Street analysts forecast BIIB stock price to rise

11 Buy

14 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

143.00

Averages

204.45

High

246.00

Current: 0.000

Low

143.00

Averages

204.45

High

246.00

BMO Capital

Evan Seigerman

Market Perform

maintain

$196

AI Analysis

2026-03-30

New

Reason

BMO Capital

Evan Seigerman

Price Target

$196

AI Analysis

2026-03-30

New

maintain

Market Perform

Reason

BMO Capital analyst Evan Seigerman says high-dose Spinraza approval and positive Phase 2 AMETHYST trial data are both \"likely positive drivers\" of Biogen shares. The firm has a Market Perform rating and $196 price target on Biogen shares, which are up $3.37, or 2%, to $187.21 in early Monday trading.

HSBC

Morten Herholdt

Reduce

maintain

$143 -> $150

2026-03-17

Reason

HSBC

Morten Herholdt

Price Target

$143 -> $150

2026-03-17

maintain

Reduce

Reason

HSBC analyst Morten Herholdt raised the firm's price target on Biogen to $150 from $143 and keeps a Reduce rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIIB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 13.80, compared to its 5-year average forward P/E of 14.15. For a more detailed relative valuation and DCF analysis to assess Biogen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

14.15

Current PE

13.80

Overvalued PE

17.62

Undervalued PE

10.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

10.35

Current EV/EBITDA

10.49

Overvalued EV/EBITDA

12.77

Undervalued EV/EBITDA

7.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.39

Current PS

2.83

Overvalued PS

4.22

Undervalued PS

2.56

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Stocks for short term gans

Intellectia · 19 candidates

Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

Liberty Global Ltd

6.07B

Phibro Animal Health Corp

2.15B

Allegiant Travel Co

2.10B

Envista Holdings Corp

4.77B

XPO Inc

23.85B

Regal Rexnord Corp

14.06B

NASDAQ100 stock with fairly or undervalue

Intellectia · 10 candidates

Analyst Consensus: Strong Buy, Moderate Buy, HoldPe Ttm: 8 - 22P/B Ratio: <= 4.00Is Index Component: NDXEv Ebitda: <= 15

Ticker

Name

Market Cap$

Diamondback Energy Inc

44.13B

PDD Holdings Inc

152.56B

PayPal Holdings Inc

53.15B

Biogen Inc

25.32B

T-Mobile US Inc

211.11B

Cognizant Technology Solutions Corp

41.28B

list of biotech stock

Intellectia · 11 candidates

Market Cap: >= 1000.00MThemes: BiotechBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

Amgen Inc

185.02B

Gilead Sciences Inc

160.18B

Vertex Pharmaceuticals Inc

117.00B

Regeneron Pharmaceuticals Inc

78.75B

Biontech SE

29.61B

Biogen Inc

25.32B

show me onlybiostock

Intellectia · 19 candidates

Themes: BiotechWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Amgen Inc

185.02B

Gilead Sciences Inc

160.18B

Vertex Pharmaceuticals Inc

117.00B

Regeneron Pharmaceuticals Inc

78.75B

Biontech SE

29.61B

Biogen Inc

25.32B

Whales Holding BIIB

Mubadala Investment Company PJSC

Pacer Advisors, Inc.

MAPFRE Asset Management

Cinctive Capital Management LP

Portolan Capital Management, LLC

PRIMECAP Management Company

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 188.38 USD — it has increased 2.47

What is Biogen Inc (BIIB)'s business?

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

What is the price predicton of BIIB Stock?

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is204.45 USD with a low forecast of 143.00 USD and a high forecast of 246.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.28B USD, decreased -7.14

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to -0.33 USD, decreased -118.03

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7500 emplpoyees as of March 30 2026.

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 26.98B USD.